Cancer genomic research at the crossroads: Realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Li, Shengwen Calvin ^a,b,d   Tachiki, Lisa May Ling ^a,b   Kabeer, Mustafa H ^a,b   Dethlefs, Brent A ^a   Anthony, Michael J ^e   Loudon, William G ^a,b,c,d  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST JOSEPH HOSPITAL   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e BIOLA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CONSENSUS SEQUENCE; COST BENEFIT ANALYSIS; DECISION MAKING; GENE MUTATION; GENE SEQUENCE; GENETIC BACKGROUND; HUMAN; METASTASIS; NONHUMAN; PRIMARY TUMOR; REVIEW; SINGLE CELL ANALYSIS; STANDARDIZATION; TUMOR MICROENVIRONMENT;

EID: 84988648759     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0115-7     Document Type: Review

References (114)

1. Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21(3):309-322.
2. Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM: Bioinformatics approaches in the study of cancer. Curr Mol Med 2007, 7(1):133-141.
3. Heng HH: Cancer genome sequencing: the challenges ahead. Bioessays 2007, 29(8):783-794.
4. LaFramboise T, Dewal N, Wilkins K, Pe'er I, Freedman ML: Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. PLoS Genet 2010, 6(9):e1001086.
5. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
6. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, Curtis C, Watts C, Tavare S: Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 2013, 110(10):4009-4014.
7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, et al: An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY 2008, 321(5897):1807-1812.
8. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
9. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (New York, NY 2009, 324(5924):261-265.
10. Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21(3):297-308.
11. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22(4):425-437.
12. Kim YW, Koul D, KimSH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK: Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro Oncol 2013, 15(7):829-839.
13. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110.
14. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al: The genomic landscapes of human breast and colorectal cancers. Science (New York, NY 2007, 318(5853):1108-1113.
15. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinsk M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, et al: Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
16. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR: Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013, 3(1):246-259.
17. Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Kenna Shaw for Trn, Strausberg RL, Yao J: Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res 2013, 19(9):2460-2472.
18. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA: Mutational landscape and significance across 12 major cancer types. Nature 2013, 502(7471):333-339.
19. Ashworth A, Hudson TJ: Genomics: comparisons across cancers. Nature 2013, 502(7471):306-307.
20. TCGA-ResNetwork: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513:202-209. (211 September 2014) doi:2010.1038/nature13480.
21. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, Kearney L, Enver T, Greaves M: Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469(7330):356-361.
22. Li SC, Lee KL, Luo J: Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies. Stem Cells Dev 2012, 21(4):503-506.
23. Bonavia R, Inda MM, Cavenee WK, Furnari FB: Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011, 71(12):4055-4060.
24. Carpenter EL, Rader J, Ruden J, Rappaport EF, Hunter KN, Hallberg PL, Krytska K, O'Dwyer PJ, Mosse YP: Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front Oncol 2014, 4:201. doi:210.3389/fonc.2014.00201.
25. Longo DL: Tumor heterogeneity and personalized medicine. N Engl J Med 2012, 366(10):956-957.
26. Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C: Parallel evolution of tumour subclones mimics diversity between tumours. J Pathol 2013, 230(4):356-364.
27. Rodler E, Korde L, Gralow J: Current treatment options in triple negative breast cancer. Breast Dis 2010, 32(1-2):99-122.
28. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, et al: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486(7403):395-399.
29. Shin SJ, Hyjek E, Early E, Knowles DM: Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006, 14(4):279-284.
30. Wemmert S, Romeike BF, Ketter R, Steudel WI, Zang KD, Urbschat S: Intratumoral genetic heterogeneity in pilocytic astrocytomas revealed by CGH-analysis of microdissected tumor cells and FISH on tumor tissue sections. Int J Oncol 2006, 28(2):353-360.
31. Corzo C, Tusquets I, Suarez M, Fabregat X, Salido M, Sole F, Corominas JM, Serrano S: Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17. Cancer Genet Cytogenet 2004, 154(1):89-90.
32. Moch H, Schraml P, Bubendorf L, Richter J, Gasser TC, Mihatsch MJ, Sauter G: Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res 1998, 58(11):2304-2309.
33. Lonn U, Lonn S, Nilsson B, Stenkvist B: Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int J Cancer 1994, 58(1):40-45.
34. Li SC, Tachiki LM, Luo J, Dethlefs BA, Chen Z, Loudon WG: A biological global positioning system: considerations for tracking stem cell behaviors in the whole body. Stem Cell Rev 2010, 6(2):317-333.
35. Bhatia S, Frangioni JV, Hoffman RM, Iafrate AJ, Polyak K: The challenges posed by cancer heterogeneity. Nat Biotechnol 2012, 30(7):604-610.
36. Marusyk A, Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010, 1805(1):105-117.
37. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152(4):714-726.
38. Bourzac K: Biology: three known unknowns. Nature 2014, 509(7502):S69-S71.
39. Li X, Lees JR: Pre-existing central nervous system lesions negate cytokine requirements for regional experimental autoimmune encephalomyelitis development. Immunology 2013, 138(3):208-215.
40. Uhr JW, Pantel K: Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011, 108(30):12396-12400.
41. Sonnenschein C, Soto AM: The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J Biosci 2013, 38(3):651-663.
42. Milbury K: Changing the Cancer Landscape. Edited by Scientific American. USA: Scientific American; 2013:1-8.
43. Nash I: Changing the cancer landscape. N Engl J Med 2012, 366:2132-2133. discussion 2133.
44. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK: Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 2013, 8(5):658-661.
45. Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM: Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013, 19(24):6967-6975.
46. Printz C: BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 2010, 116(14):3307-3308.
47. Rubin EH, Anderson KM, Gause CK: The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. Cancer Discovery 2011, 1(1):17-20.
48. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA: High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2011, 2:82-93.
49. Beckman RA, Loeb LA: Negative clonal selection in tumor evolution. Genetics 2005, 171(4):2123-2131.
50. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suva ML, Regev A, Bernstein BE: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014, 344:1396-1401.
51. Beckman RA, Schemmann GS, Yeang CH: Impact of genetic dynamics and singlecell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci U S A 2012, 109(36):14586-14591.
52. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
53. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWMM, Hayes DF: Circulating tumor cells versus imaging -predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409.
54. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221.
55. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM, Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009, 4(1):30-36.
56. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, Paterlini-Brechot P: Isolation by size of epithelial tumor cells -A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000, 156:57-63.
57. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M: Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 2012, 130:1590-1597.
58. Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DSW, Lim WT, Han J, Bhagat AAS, Lim CT: Isolation and retrieval of circulating tumor cells using centrifugal forces. Scientific Reports 2013, 3:Article number: 1259. doi:1210.1038/srep01259.
59. Neeves KB: Catch me if you can: isolating circulating tumor cells from flowing blood. Clin Chem 2012, 58(5):803-804.
60. Navin N, Hicks J: Future medical applications of single-cell sequencing in cancer. Genome Med 2011, 3:31.
61. Shapiro E, Biezuner T, Linnarsson S: Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat Rev Genet 2013, 14:618-630.
62. Huang CL, Yokomise H, Fukushima M, Kinoshita M: Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2006, 2:289-299.
63. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, et al: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013, 45:1470-1473.
64. Kelley RK, Venook AP: Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer 2011, 10:73-80.
65. Kelley RK, Van Bebber SL, Phillips KA, Venook AP: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Cancer Netw 2011, 9:13-25.
66. Davies K: The $1000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine. New York: Free Press; 2010.
67. Warren AD, Kwong GA, Wood DK, Lin KY, Bhatia SN: Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci U S A 2014, 111:3671-3676.
68. Vandin F, Upfal E, Raphael BJ: De novo discovery of mutated driver pathways in cancer. Genome Res 2013, 22(2):375-385.
69. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW: Cancer genome landscapes. Science 2013, 339(6127):1546-1558.
70. Goymer P: Natural selection: the evolution of cancer. Nature 2008, 454(7208):1046-1048.
71. TCGA-2: From TCGA to treatment. Cancer Discovery 2013, 2(12):1068.
72. Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH: Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell 2013, 24(2):197-212.
73. Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A: Targeting of TGF beta signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA 2013, 19:177-190.
74. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR, Gillespie GY: Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE 2012, 7(1):e29653.
75. Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY: Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 2011, 6:e16080.
76. Ramakrishnan V, Kushwaha D, Koay DC, Reddy H, Mao Y, Zhou L, Ng K, Zinn P, Carter B, Chen CC: Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark 2011, 10:185-193.
77. Majchrzak-Celinska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska AM, Nowak S, Baer-Dubowska W: Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet 2013, 54:335-344.
78. Griffin JL: Metabolic profiles to define the genome: can we hear the phenotypes? Philos T Roy Soc B 2004, 359(1446):857-871.
79. Warburg O: On respiratory impairment in cancer cells. Science 1956, 124:269-270.
80. Flier JS, Mueckler MM, Usher P, Lodish HF: Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987, 235:1492-1495.
81. DeBerardinis RJ, Thompson CB: Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012, 148(6):1132-1144.
82. Oermann EK, Wu J, Guan KL, Xiong Y: Alterations of metabolic genes and metabolites in cancer. Semin Cell Dev Biol 2012, 23(4):370-380.
83. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
84. Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11(5):325-337.
85. Sotgia F, Martinez-Outschoorn UE, Lisanti MP: Cancer metabolism: new validated targets for drug discovery. Oncotarget 2013, 4(8):1309-1315.
86. Muoio VMF, Shinjo SO, Matushita H, Rosemberg S, Teixeira MJ, Marie SKN: Extraneural metastases in medulloblastoma. Arq Neuropsiquiatr 2011, 69(2-B):328-331.
87. Piccirilli M, Brunetto GM, Rocchi G, Giangaspero F, Salvati M: Extra central nervous system metastases from cerebral glioblastoma multiforme in elderly patients. Clinico-pathological remarks on our series of seven cases and critical review of the literature. Tumori 2008, 94(1):40-51.
88. Alexander M, Mellor JD, McArthur G, Kee D: Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. MedJ Austr 2014, 201(1):49-53.
89. Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E: High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008, 39(3):151-156.
90. Savas P, Caramia F, Teo ZL, Loi S: Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. Curr Opin Oncol 2014, 26:562-567.
91. Li SC, Jin Y, Loudon WG, Song Y, Ma Z, Weiner LP, Zhong JF: From the cover: increase developmental plasticity of human keratinocytes with gene suppression. Proc Natl Acad Sci U S A 2011, 108(31):12793-12798.
92. Li SC, Han YP, Dethlefs BA, Loudon WG: Therapeutic window, a critical developmental stage for stem cell therapies. Curr Stem Cell Res Ther 2010, 5:293-297.
93. Mukherjee S: THE EMPEROR OF ALL MALADIES: A Biography of Cancer, Reprint edition (August 9, 2011) edn. New York, NY: Scribner; a division of Simon & Schuster Inc; 2010:1-608.
94. Beckman RA, Loeb LA: Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005, 15(6):423-435.
95. Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008, 68(10):3551-3557. discussion 3557.
96. Beckman RA, Loeb LA: Efficiency of carcinogenesis with and without a mutator mutation. Proc Natl Acad Sci U S A 2006, 103(38):14140-14145.
97. Beckman RA, Clark J, Chen C: Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov 2014, 10:735-748.
98. Beckman RA: Efficiency of carcinogenesis: is the mutator phenotype inevitable? Semin Cancer Biol 2014, 20:340-352.
99. Li SC, Loudon WG: A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors. Cancer Cell Int 2008, 8:9 (page 1-11).
100. Saporito B: The new cancer dream teams, why amassing a huge cast of PhDs and funding them lavishly might just beat the tumors. TIME 2013, 181(12):30-38.
101. Schroeder MP, Gonzalez-Perez A, Lopez-Bigas N: Visualizing multidimensional cancer genomics data. Genome Med 2013, 5:9.
102. Duraipandian S, Sylvest Bergholt M, Zheng W, Yu Ho K, Teh M, Guan Yeoh K, Bok Yan So J, Shabbir A, Huang Z: Real-time Raman spectroscopy for in vivo, online gastric cancer diagnosis during clinical endoscopic examination. J Biomed Opt 2012, 17:081418.
103. Zhuang Z, Li N, Guo Z, Zhu M, Xiong K, Chen S: Study of molecule variations in renal tumor based on confocal micro-Raman spectroscopy. J Biomed Opt 2013, 18:31103.
104. Surmacki J, Musial J, Kordek R, Abramczyk H: Raman imaging at biological interfaces: applications in breast cancer diagnosis. Mol Cancer 2013, 12:48.
105. Wu L, Wang Z, Zong S, Chen H, Wang C, Xu S, Cui Y: Simultaneous evaluation of p53 and p21 expression level for early cancer diagnosis using SERS technique. Analyst 2013, 138(12):3450-3456.
106. Zavaleta CL, Garai E, Liu JT, Sensarn S, Mandella MJ, Van de Sompel D, Friedland S, Van Dam J, Contag CH, Gambhir SS: A Raman-based endoscopic strategy for multiplexed molecular imaging. Proc Natl Acad Sci U S A 2013, 110:E2288-E2297.
107. Dinish US, Balasundaram G, Chang YT, Olivo M: Sensitive multiplex detection of serological liver cancer biomarkers using SERS-active photonic crystal fiber probe. J Biophotonics 2013, doi: 10.1002/jbio.201300084.
108. Ranganathan S, Schonbach C, Kelso J, Rost B, Nathan S, Tan TW: Towards big data science in the decade ahead from ten years of InCoB and the 1st ISCB-Asia Joint Conference. BMC Bioinformatics 2013, 12(Suppl 13):S1.
109. Schadt EE, Linderman MD, Sorenson J, Lee L, Nolan GP: Computational solutions to large-scale data management and analysis. Nat Rev Genet 2010, 11(9):647-657.
110. Tsiknakis M, Promponas VJ, Graf N, Wang MD, Wong ST, Bourbakis N, Pattichis CS: Guest editorial: computational solutions to large-scale data management and analysis in translational and personalized medicine. IEEE J Biomed Health Inform 2010, 18:720-721.
111. Previati M, Manfrini M, Galasso M, Zerbinati C, Palatini J, Gasparini P, Volinia S: Next generation analysis of breast cancer genomes for precision medicine. Cancer Lett 2013, 339:1-7.
112. McClellan J, King MC: Genetic heterogeneity in human disease. Cell 2013, 141:210-217.
113. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H, Nimgaonkar VL, Go RC, Savage RM, Swerdlow NR, Gur RE, Braff DL, King MC, McClellan JM: Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 2013, 154:518-529.
114. McClellan J, King MC: Genomic analysis of mental illness: a changing landscape. JAMA 2013, 303:2523-2524.